| 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2025-028 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 健帆生物科技集团股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、现金管理的品种：拟使用闲置自有资金购买安全性高、流动性好、且投 资期限最长不超过 12 个月的理财产品，不用于委托贷款等财务性投资以及证券 投资、衍生品投资等高风险投资，不购买以股票及其衍生品、无担保债券为投资 标的的理财产品。 5、特别风险提示：尽管公司购买安全性高、流动性好的理财产品，且在购 买前都经过严格的评估和审核，但是金融市场受宏观经济的影响较大，不排除该 项投资受到市场波动的影响。此外，公司将根据经济形势以及金融市场的变化适 时适量地介入，因此短期投资的实际收益不可预期，敬请广大投资者注意投资风 险。 健帆生物科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 15 日 召开第五届董事会第二十七次会议和第五届监事会 ...

按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部 控制评价结果推测未来内部控制的有效性具有一定的风险。 二、内部控制评价结论 健帆生物科技集团股份有限公司 2024 年度内部控制自我评价报告 健帆生物科技集团股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和要求，结合健帆生物 科技集团股份有限公司（以下简称"公司"） 内部控制制度和评价办法，在内部 日常监督和专项监督的基础上，我们对公司 ...

健帆生物科技集团股份有限公司 董事会审计委员会对会计师事务所 2024 年度履职情况评估及履 行监督职责情况的报告 致同会计师事务所（特殊普通合伙）（以下简称"致同"）前身是北京市财政 局于 1981 年成立的北京会计师事务所，1998 年 6 月脱钩改制并与京都会计师事 务所合并，2011 年经北京市财政局批准转制为特殊普通合伙，2012 年更名为致 同会计师事务所（特殊普通合伙），注册地址为北京市朝阳区建国门外大街 22 号 赛特广场 5 层，执业证书颁发单位及序号为北京市财政局 NO. 0014469，首席合 伙人为李惠琦先生。 截至 2024 年末，致同从业人员近 6000 人，其中合伙人 239 名，注册会计师 1359 名，签署过证券服务业务审计报告的注册会计师超过 400 人。 二、 聘任年审会计师事务所履行的程序 公司于 2024 年 4 月 25 日召开的第五届董事会第十八次会议、第五届监事会 第十三次会议审议通过了《关于 2023 年度审计费用的确认及续聘 2024 年度审计 机构的议案》，该议案已经公司第五届董事会独立董事 2024 年第三次专门会议审 议通过并取得全体独立董事同意，该议 ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-024 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于参加深圳证券交易所"成长新启航·民企百舸竞中流" 2024 年度集体业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 3、召开方式：视频直播与图文转播 4、公司出席人员：公司董事兼财务总监廖雪云女士，董事会秘书黄聪女士 二、投资者问题征集方式 为充分尊重投资者、提升交流的针对性，现就本次业绩说明会提前向投资者 公开征集问题，广泛听取投资者的意见和建议。投资者可提前登陆深交所"互动 易"平台（http://irm.cninfo.com.cn）"云访谈"栏目进入本次业绩说明会页面，或扫 描二维码（附后）进入问题征集专题页面进行提问。公司将在本次业绩说明会上 对投资者普遍关注的问题进行回答。 1 健帆生物科技集团股份有限公司（以下简称"公司"）将于 2025 年 4 月 18 日（星期五）15:00－17:00 参加由深圳证券交易所组织召开的以"成长新启航·民 企百舸竞中流"为主题的集体业绩说明会活动， ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-026 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2024 年度股东大会。 2、股东大会的召集人：董事会。公司第五届董事会第二十七次会议审议通 过了《关于召开 2024 年度股东大会的议案》。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件、深交所业务规则和《公司章程》等规定。 4、会议召开时间： （1）现场会议时间：2025 年 5 月 7 日（星期三）下午 14:30； （2）网络投票时间：2025 年 5 月 7 日（星期三）。其中：通过深圳证券交易 所交易系统进行投票的时间为 2025 年 5 月 7 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易所交易互联网投票系统投票的时间为 2025 年 5 月 7 日 9:15 至 15:00。 ...

健帆生物科技集团股份有限公司 第五届监事会第十九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 健帆生物科技集团股份有限公司（以下简称"公司"）第五届监事会第十九 次会议于 2025 年 4 月 15 日在公司会议室以现场会议及通讯表决的方式召开，本 次会议应出席监事 3 人，实际出席监事 3 人。本次会议通知提前以电子邮件及电 话通知等方式向全体监事送达，会议由监事会主席彭小红先生主持，会议的召开 符合《中华人民共和国公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事认真讨论，审议并表决通过了以下议案： 1、 审议通过了《2024 年年度报告》及《2024 年年度报告摘要》 | 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2025-016 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 监事会认为：公司董事会编制和审核的公司《2024 年年度报告》及其摘要的 程序符合法律、行政法规和中国证监会的相关规定，报告内容真实、准确、完 ...

1、 审议通过了《2024 年年度报告》及《2024 年年度报告摘要》 | 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2025-015 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 健帆生物科技集团股份有限公司 第五届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 健帆生物科技集团股份有限公司（以下简称"公司"）第五届董事会第二十 七次会议于 2025 年 4 月 15 日在公司会议室以现场会议及通讯表决的方式召开， 本次会议应出席董事 9 人，实际出席董事 9 人，符合《公司法》和公司章程的有 关规定。本次会议通知提前以电子邮件及电话通知等方式向全体董事送达。公司 董事长董凡先生召集和主持了本次会议，公司监事和高级管理人员列席了会议。 本次董事会的召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认真讨论，审议并表决通过了以下议案： 本议案已经公司战略委员会审议通过。《2024 年度环境、社会及公司 ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-020 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）于2025 年4 月15 日 召开第五届董事会第二十七次会议和第五届监事会第十九次会议，审议通过了 《关于 2024 年度利润分配预案的议案》，现将相关事项说明如下： 一、审议程序 （一）董事会意见 公司 2024 年度利润分配预案尚需经公司 2024 年度股东大会审议通过后方 可实施，存在不确定性，敬请广大投资者理性投资，注意投资风险。 二、2024 年度利润分配方案的基本情况 （一）2024 年度的财务情况 公司第五届董事会第二十七次会议审议通过了《关于 2024 年度利润分配预 案的议案》，公司董事会认为：公司综合考虑投资者的合理回报和公司的长远发 展，在保证正常经营业务发展的前提下拟定的《2024 年度利润分配预案》符合公 司实际情况，符合《公司法》《公司章程》的规定，同意将 ...

Financial Performance - The company's revenue for Q1 2025 was ¥547.84 million, a decrease of 26.40% compared to ¥744.34 million in the same period last year[5]. - Net profit attributable to shareholders was ¥188.78 million, down 33.71% from ¥284.77 million year-on-year[5]. - The net cash flow from operating activities was ¥269.05 million, a decline of 46.94% from ¥507.10 million in the previous year[5]. - Total operating revenue decreased to ¥547,835,977.14 from ¥744,336,658.85, representing a decline of approximately 26.4%[30]. - Net profit for the period was ¥188,177,307.35, down from ¥283,928,180.04, reflecting a decline of approximately 33.6%[32]. - Operating profit decreased to ¥236,505,672.18 from ¥348,716,883.42, a drop of around 32.1%[31]. - Basic earnings per share decreased to ¥0.2328 from ¥0.3512, a decline of approximately 33.7%[32]. Cash Flow and Investments - The company reported a significant increase in trading financial assets, rising by 257.66% to ¥2.12 billion due to new investment in financial products[9]. - Cash received from sales and services decreased by 31.08% to approximately ¥605.51 million compared to the same period last year[16]. - Cash inflow from investment activities increased by 53.39% to approximately ¥651.29 million, mainly due to increased redemption of financial products compared to the previous year[18]. - Cash outflow from investment activities rose by 72.68% to approximately ¥2.18 billion, primarily due to increased purchases of financial products[18]. - Cash flow from investing activities resulted in a net outflow of ¥1,531,094,735.02, compared to a net outflow of ¥839,267,821.10 in the previous period[36]. - Cash flow from financing activities showed a net inflow of approximately ¥15.94 million, a turnaround from a net outflow in the previous period[18]. - Cash flow from financing activities showed a net inflow of ¥15,942,579.95, contrasting with a net outflow of ¥93,208,529.89 previously[36]. Assets and Liabilities - Total assets increased by 5.57% to ¥5.68 billion from ¥5.38 billion at the end of the previous year[5]. - The company reported a total asset of CNY 5,683,427,238.87 as of March 31, 2025, an increase from CNY 5,383,449,076.46 at the beginning of the period[25]. - The total liabilities increased to CNY 2,151,297,896.21 from CNY 2,048,784,541.14, reflecting a rise in financial obligations[27]. - The company's total equity rose to CNY 3,532,129,342.66 from CNY 3,334,664,535.32, showing growth in shareholder value[28]. - The company’s short-term borrowings decreased to CNY 54,883,755.70 from CNY 77,505,234.56, indicating a reduction in short-term debt[26]. - The company’s long-term borrowings increased to CNY 132,589,555.61 from CNY 97,898,471.20, indicating a strategy to finance long-term growth[27]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 52,502[20]. - The largest shareholder, Dong Fan, holds 44.47% of the shares, totaling approximately 355.13 million shares[20]. - The company has a total of 286,138,075 shares under lock-up agreements, with no shares released during the reporting period[22]. Operational Efficiency - The gross profit margin for the reporting period was 80.74%, with a net profit margin of 34.46%[9]. - The company’s accounts receivable decreased to CNY 35,573,787.10 from CNY 53,455,197.95, suggesting improved collection efficiency[25]. - The company’s inventory increased slightly to CNY 344,866,977.28 from CNY 337,786,618.28, indicating stable inventory management[25]. - The company reported a significant increase of 122.06% in cash received from other operating activities, amounting to approximately ¥52.64 million, mainly due to increased government subsidies[16]. - The company’s retained earnings increased to CNY 2,703,111,264.76 from CNY 2,514,327,667.79, reflecting profitability over the period[28]. - Research and development expenses slightly decreased to ¥52,980,606.72 from ¥54,171,638.09, a reduction of about 2.2%[31]. Financial Expenses - The company experienced a 2198.73% increase in financial expenses, totaling ¥10.95 million, primarily due to increased financial product investments[12]. - Financial expenses increased significantly to ¥10,950,286.71 from ¥476,362.26, marking an increase of approximately 2,303.5%[31].

Financial Performance - The company's operating revenue for 2024 reached ¥2,677,320,710.76, representing a 39.27% increase compared to ¥1,922,348,169.84 in 2023[19]. - The net profit attributable to shareholders for 2024 was ¥820,195,432.44, an 87.91% increase from ¥436,492,212.29 in 2023[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥779,044,218.02, up 90.46% from ¥409,043,029.02 in 2023[19]. - The company's cash flow from operating activities for 2024 was ¥1,050,988,421.40, a 14.64% increase from ¥916,743,866.89 in 2023[19]. - The basic earnings per share for 2024 was ¥1.05, reflecting a 90.91% increase compared to ¥0.55 in 2023[19]. - The total assets at the end of 2024 were ¥5,383,449,076.46, a decrease of 2.88% from ¥5,543,301,641.00 at the end of 2023[19]. - The net assets attributable to shareholders at the end of 2024 were ¥3,333,906,225.54, an increase of 5.92% from ¥3,147,475,025.76 at the end of 2023[19]. - The overall gross margin for the reporting period was 80.78%, with a gross margin of 85.01% for blood perfusion products, indicating strong profitability and market competitiveness[62]. - The company reported a total of ¥4,325,000,000.00 in new purchases of trading financial assets during the reporting period[119]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 8.00 RMB per 10 shares (including tax) to all shareholders based on the total share capital as of the record date for the 2024 profit distribution plan[5]. - The company completed a share repurchase of ¥5 billion, with a cumulative dividend payout since its IPO amounting to ¥34.51 billion, which is 2.45 times the amount raised during the IPO and refinancing[89]. - The company plans to distribute a cash dividend of 620 million RMB for 2024, with a proposed payout ratio exceeding 75%[149]. - The company issued a cash dividend of 310 million RMB for the 2023 fiscal year, with a payout ratio of 70%[149]. - The total cash dividend amount, including other methods, reached 1,119,383,525.57 RMB, representing 100% of the distributable profit[200]. Research and Development - R&D investment for the reporting period was 240 million yuan, accounting for 8.97% of total revenue, with 28 registered medical device products, 25 of which are Class III[54]. - The company employs 486 R&D personnel, representing 17.38% of total employees, with over 30% holding postgraduate degrees[53]. - The company has received 27 authorized patents during the reporting period, including 17 invention patents, bringing the total to 373 authorized patents[84]. - The company is focused on continuous innovation in medical devices, particularly in the field of blood purification and renal therapy[110]. - The R&D strategy includes launching new products, with a focus on blood purification consumables and devices, while improving existing product performance[134]. Market and Product Development - The global medical device market size in 2023 was $582.6 billion, with a year-on-year growth of 9.35%, and is expected to reach $617.6 billion in 2024[29]. - The Chinese medical device market size in 2023 was ¥1,032.8 billion, with a year-on-year growth of 7.79%, and is projected to reach ¥1,110.3 billion in 2024[29]. - The company specializes in the research, development, production, and sales of high-tech medical devices, focusing on innovative blood purification products for various critical conditions[40]. - The company has developed disposable blood perfusion devices for various diseases, including HA series, KHA series, and pHA series for chronic kidney disease patients, addressing individual treatment needs[41]. - The company has established partnerships with over 80 large hospitals for clinical application research, enhancing its market presence[53]. Operational Efficiency and Management - The company has implemented automation and AI technologies in its production processes, improving efficiency and product quality[57]. - The company has initiated a comprehensive digital infrastructure upgrade to enhance operational efficiency and integrate technology with business processes[87]. - The company has a complete organizational structure, including a shareholders' meeting, board of directors, and supervisory board, ensuring effective corporate governance[167]. - The company has established a complete and independent financial department with a standardized financial accounting system, ensuring independent financial decision-making[167]. - The company has a robust internal management structure that operates independently from its controlling shareholders[167]. Social Responsibility and Compliance - The company donated cash and materials valued at ¥38.3 million for various social responsibility initiatives, including charity and public health projects[92]. - The company actively engages with stakeholders and fulfills social responsibilities in areas such as environmental protection and public welfare[165]. - The company has committed to enhancing legal compliance training for its directors and related personnel following a trading incident[183]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[163]. Future Outlook and Strategic Goals - The company will continue to focus on the blood purification field and expand into international markets, targeting chronic diseases such as uremia and liver disease[133]. - The company aims to enhance its product line and technical strength through mergers and acquisitions, leveraging capital market tools[133]. - The company plans to establish suitable production bases to ensure capacity and enhance manufacturing capabilities through smart manufacturing[134]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $30 million allocated for potential mergers[176]. - The company has a clear strategy for independent operations, ensuring no overlap with the interests of its controlling shareholders[167].